✨ Free AI Report
Acurx Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Acurx Pharmaceuticals, Inc.
Company Research

Acurx Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates w...

Analyst-debate audio for Acurx Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Acurx Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

High-risk, high-reward antibiotic developer in an underserved market segment facing typical clinical-stage biotech volatility and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Acurx Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Acurx Pharmaceuticals, Inc. Overview

Pro stress-test →

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates with a Gram-positive selective spectrum that blocks the bacterial enzyme DNA polymerase IIIC, inhibiting DNA replication and leading to Gram-positive bacterial cell death.

Strategic Profile

Pro stress-test →

Its R&D pipeline targets Gram-positive bacteria, including Clostridioides difficile, MRSA, vancomycin resistant Enterococcus, drug-resistant Streptococcus pneumoniae, and B. anthracis. The company began a Phase 2 clinical trial in August 2026 with expected completion in November 2027, with plans for Phase 3 advancement in recurrent CDI.

Competitive Landscape

Pro stress-test →

Acurx targets Gram-positive pathogens including CDI, MRSA, VRE, DRSP, and anthrax through a proprietary DNA polymerase IIIC inhibition mechanism. Direct competitors include traditional antibiotic developers and specialty infectious disease biotech firms, though few companies focus specifically on the Gram-positive selective spectrum approach.

Industry Context

Acurx Pharmaceuticals, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2017 · Headquarters: Staten Island, New York, US · Employees: Not publicly disclosed · Revenue: Pre-revenue, clinical-stage company · Market cap: $5.35M (as of February 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Acurx Pharmaceuticals, Inc..

  • In February 2026, the USPTO granted a new patent for DNA pol IIIC inhibitors covering composition of matter and method of use, extending to December 2039, strengthening IP moat in differentiated antibiotic approach.
  • Phase 2 trial for ibezapolstat in recurrent CDI began August 2026 with expected completion November 2027, marking material clinical progression toward Phase 3 registration trial targeting FDA approval.

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2026Phase 2 clinical trial initiated for ibezapolstat in recurrent CDI with expected completion November 2027
  • February 2026USPTO granted patent for DNA pol IIIC inhibitors extending through December 2039
  • +1 moreTrack every material event for Acurx Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Acurx Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Spero TherapeuticsNovel antibiotics for Gram-negative and difficult-to-treat infections→Paratek PharmaceuticalsNovel antibiotics for resistant bacterial infections→Iterum TherapeuticsAntibiotic development for Gram-positive and Gram-negative infections→Videregen BiotechnologyNovel antibiotics targeting resistant pathogens→

Compare Acurx Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Acurx Pharmaceuticals, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Acurx Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Acurx Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Acurx Pharmaceuticals, Inc. do this quarter?”
“Is Acurx Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Acurx Pharmaceuticals, Inc. do?+
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates w...
What is Acurx Pharmaceuticals, Inc.'s Cyborg Score?+
Acurx Pharmaceuticals, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Acurx Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Spero Therapeutics, Paratek Pharmaceuticals, Iterum Therapeutics, Videregen Biotechnology. The full competitive landscape is in the AskCyborg report.
How can I get the full Acurx Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Acurx Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Acurx Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.